Efficacy of Inebilizumab in N‐ <scp>MOmentum</scp> Trial Participants With or Without Prior Immunosuppressants
B-cell-depleting monoclonal antibody, in participants with aquaporin-4-seropositive neuromyelitis optica spectrum disorder from the N-MOmentum trial (NTC02200770). Inebilizumab treatment resulted in a sustained low annualized attack rate relative to the pretrial annualized attack rate and a high probability of remaining attack-free for up to 4 years among participants with and without prior immunosuppressant use. Based on modeling data, inebilizumab had greater long-term efficacy than historical immunosuppressants. Inebilizumab was well tolerated regardless of prior immunosuppressant use.
Authors
- Beatrice Suero
- S. Walsh
- Dewei She
- Dustin Cavida
- Daniel Cimbora
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Ho Jin Kim (ORCID: https://orcid.org/0000-0002-8672-8419)
- Romain Marignier (ORCID: https://orcid.org/0000-0002-5967-2800)
- John W. Lindsey
- Bruce A. C. Cree (ORCID: https://orcid.org/0000-0001-7689-2533)
Institutions
- Amgen (United States) (US)
- University of California, San Francisco (US)
- Humboldt-Universität zu Berlin (DE)
- Observatoire Français de la Sclérose en Plaques (FR)
- Hôpital Pierre Wertheimer (FR)
- National Cancer Center (KR)
- EVERSANA (Canada) (CA)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1002/acn3.70426
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen